New drug tested to save transplanted kidneys from silent attack
NCT ID NCT07274462
Summary
This study is testing whether a drug called daratumumab can reduce harmful inflammation in the blood vessels of transplanted kidneys, a condition that can lead to organ failure. Kidney transplant recipients with this specific type of inflammation will receive either the drug or standard monitoring for one year. Researchers will check if the drug improves the health of the kidney tissue and helps the transplant last longer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MICROVASCULAR INFLAMMATION - MVI IN KINDEY TRANSPLANT RECIPIENTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Transplant-nephrology department
Martin, 036 01, Slovakia
Conditions
Explore the condition pages connected to this study.